www new psychoactive substances: awareness & responses

Transcription

1 www new psychoactive substances: awareness & responses

2 aims & objectives what are nps? the history some case studies what can I do?

3 quiz Using a Smart phone go to: kahoot.it Wait for the code to come up and then type it in

4 definition: problems of doing so psychoactive substance means any substance which (a) is capable of producing a psychoactive effect in a person who consumes it, and (b) is not an exempted substance (alcohol, nicotine, caffine, painkillers, drugs already classified under the missue of drugs act etc.)

5 a key statistic: emcdda 2016 report First time drop off since 2008 specifically synthetic cannabinoids, the nps of choice for yp

6 drugs trends are constantly changing 2000 s mephedrone ( MCAT ) 2010 s synthetic cannabinoid ( SPICE ) what does this show us?

7 psychoactive substances act 2016: a reflection what has changed? shops shut down internet buying or own production only way allowed the return of older favourites : mdma

8 remember the role of technology emerging trends: new psychoactive substances:

9 background: emerging trends: new psychoactive substances:

10 think families: Outer ring: Controlled under the Misuse of Drugs Act 1971 or The Human Medicines Regulations 2012 Inner ring: Controlled under the Psychoactive Substances Act 2016 emerging trends: new psychoactive substances:

11 case study synthetic cannabinoid receptor agonists

12 synthetic cannabinoid receptor agonists brand names are not reliable indicators of what is consumed constituents and dosages vary greatly between products and between batches difference in packets. Uneven spraying and bottom of the bag some contain more than 1 SCRA, on average 2.6 substances per packet some stimulant drugs have been named SPICE to get sales!

13 what am I getting? Classical cannabinoids (e.g. HU-210) Cyclohexylphenols (e.g. CP 47,497 and homologues of CP 47,497) Naphthoylindoles (e.g. JWH- 018, JWH-073 and JWH-398) Naphthylmethylindenes Naphthoylpyrroles Naphthylmethylindoles Phenylacetylindoles (i.e. benzoylindoles, e.g. JWH-250) NPS 2016

14 synthetic cannabinoid receptor agonists approximately 200 different SCRA s exist the largest reported NPS in UK, Europe & Globally (2015) Classically smoked as a herbal preparation : inert herbal mixture + liquid/sprayed on = classic SC Now seeing a rise in oral, powder and injectable forms Can even be sold as an e-liquid (for use in electronic cigarettes)

15 synthetic cannabinoid receptor agonists SCRAs and natural cannabis (THC) bind to the CB1 and CB2 receptors. The greater the affinity to the CB1 receptor, the higher the psycho-pharmacological activity of the agonist compound SCRA have a much higher affinity for those receptors, therefore stronger effects Remember, similar to THC but not the same. May have other biological actions, which may explain some of the differences in severity and toxicity Have the potential to activate high levels of serotonin receptors meaning potential risk of serotonin toxicity Do not contain cannabidiol (CBD) which regulates THC in cannabis

16 the changing shape of cannabis & its alternatives THC Tetrahydrocannabinol classic cannabis herbal & resin CBD cannabinol

17 the changing shape of cannabis & its alternatives THC Tetrahydrocannabinol skunk cannabis CBD cannabinol

18 the changing shape of cannabis & its alternatives Synthetic version of THC Synthetic Cannabinoids???

19 case study white powders stimulants, empathogens & dissociatives

20 white powders mdma pmma cocaine ketamine mephedrone mephamphetaimine

21 white powders: why? stimulant/empathogens: party/enjoyment chemsex: increasing sexual enjoyment, particularly m2m

22 case study fentanyl opioid

23 fentanyl: what is this? synthetic opioid primarily used in hospitals for severe pain 50 times stronger than morphine bought illicitly online compound not always mixed effectively seen in the media: Prince death but not currently popular for young people

24 fentanyl: challenge the myth adult population small amounts of use in UK no clear indication of entrenched use

25 harm reduction: if someone is going to use, what can we say? always a naïve user grain of rice/matchstick head allow time before re-dosing mental health/wellbeing: what s the impact? poly-use: avoid remember these are drugs!

26 let us put this into some context but what happens if that s not there? or the supermarket is shut and the only option is a smaller shop? if we want a cola drink we have to compromise. it might not be as good or it may be better than we thought if it is not as good, next time we go back we return to what we know

27 we go with what we know new psychoactive substances? cannabis? mdma? alcohol?

28 nps: what should we do? think family, not drug effective screening referral pathways safeguarding decisions made the same as with any other substance misuse issue

29 nps: screening not what do you use? instead why do you use? what does it do to you? what or who does it effect? what changes do you want to make?

30 nps: referral effective screening gives you the information how do you sell a referral for support?

31 some final thoughts what action are you going to take away from this? what can your team do differently?

32 CGL: POWEPOINT CONFIDENTIALITY NOTICE The contents of this presentation are at least OFFICIAL unless otherwise labelled; Privileged and or Confidential. If you are not the intended recipient of this presentation (or responsible for delivery of the presentation to such person), you may not copy or send this presentation or its contents or attachments to anyone other than the recipient. Should you not be the intended recipient you should delete this presentation immediately and notify the sender by reply as soon as possible. Opinions, conclusions and other information in this presentation that do not relate to the official business of change, grow, live shall be understood as being neither given nor endorsed by change, grow, live or its Trustees. Change, grow, live is a registered charity in England and Wales ( ) and in Scotland (SC039861). Company Registration Number (England and Wales). Registered Office: 3rd Floor, Tower Point, 44 North Road, Brighton, BN1 1YR Young people, substance use and the criminal justice system: defining the challenge and developing responses

33 Resources referenced in powerpoint: free game based learning platform Latest trends, prevalence and concerns in Europe NPS report views from young people on trends categories of drugs, effects and interventions If you require advice, information or support please do not hesitate to contact CGL Wakefield or